Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma

Inclusion Criteria: * 18 years of age or older * At most one prior chemotherapy regimen for unresectable or metastatic disease. Any adjuvant chemotherapy must have been completed more than 12 months prior to beginning protocol therapy * Histologically or cytologically confirmed adenocarcinoma of the pancreas * At least one measurable lesion according to RECIST criteria that has not been irradiated * Adequate laboratory parameters as outlined in protocol * Anticoagulation with coumadin is permitted, but PT/INR must be monitored closely, given the drug-drug interaction between coumadin and capecitabine * Negative serum pregnancy test within 14 days prior to registration Exclusion Criteria: * Pregnant or lactating women * Life expectancy \< 3 months * Serious, uncontrolled, concurrent infection(s) * Any prior oxaliplatin or fluoropyrimidine therapy * More than one prior chemotherapy regimen for unresectable or metastatic disease * Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil or platinum compounds * Any active second malignancy * Clinically significant cardiac disease or myocardial infarction within the last 12 months * Evidence of CNS metastases or history of uncontrolled seizures, central nervous system disorders or psychiatric disability * Other serious uncontrolled medical conditions * Major surgery within 4 weeks of the start of study treatment, without complete recovery * Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome * Known, existing uncontrolled coagulopathy